Vemurafenib for BRAFV600E-positive Metastatic Papillary Thyroid Cancer – Authors' Response

The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(16)30520-4
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Elsevier BV

Related search

BRAFV600E Mutation and Papillary Thyroid Cancer—In Reply

JAMA - Journal of the American Medical Association
Medicine
2013English

The Prevalence and Prognostic Value of BRAFV600E Mutation in Papillary Thyroid Cancer

International Journal of Human and Health Sciences (IJHHS)
2019English

Neck Metastatic Disease in Multifocal Thyroid Papillary Cancer

Haseki Tip Bulteni
Medicine
2018English

IL-12 Immunotherapy of BrafV600E-induced Papillary Thyroid Cancer in a Mouse Model

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2015English

Metastatic Papillary Thyroid Cancer Diagnosed and Treated During Pregnancy

Turk Otolarengoloji Arsivi/Turkish Archives of Otolaryngology
2016English

Surgical Tactics Optimization for Treatment of BRAF Positive Papillary Thyroid Cancer

Clinical and experimental thyroidology
2018English

Clinical Implication of the BRAFV600E Mutation in Papillary Thyroid Carcinoma

World Journal of Surgical Oncology
SurgeryOncology
2013English

Metastatic Papillary Thyroid Cancer in Tuberculous Lymphadenopathy: An Unfortunate Dual Pathology

Gazi Medical Journal
Medicine
2018English

Total Thyroidectomy for Papillary Thyroid Cancer

VideoEndocrinology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy